Page last updated: 2024-11-13

uridine diphosphate n-acetylmuramic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Uridine Diphosphate N-Acetylmuramic Acid: A nucleoside diphosphate sugar which is formed from UDP-N-acetylglucosamine and phosphoenolpyruvate. It serves as the building block upon which peptidoglycan is formed. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

UDP-N-acetyl-alpha-D-muramate(3-) : A UDP-N-acetyl-D-muramate(3-) in which the anomeric centre of the pyranose fragment has alpha-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID24772978
CHEBI ID70757
MeSH IDM0022353

Synonyms (16)

Synonym
udp-n-acetylmuramic acid
dihydro-udp-n-acetylmuramic acid
udp-n-acetyl-d-muramate
dihydro-udp-murnac
dihydro-udp-n-acetylmuramate
uridine diphosphate n-acetylmuramic acid
-o-[(1r)-1-carboxyethyl]-2-acetoxy-2-deoxy-d-glucopyranose
udp-n-acetyl-alpha-d-muramate
udp-n-acetylmuramoyl
uridine 5'-(3-{2-acetylamino-3-o-[(r)-1-carboxylatoethyl]-2-deoxy-alpha-d-glucopyranosyl} diphosphate)
udp-n-acetyl-alpha-d-muramate(3-)
CHEBI:70757
3ISS
Q27139067
(2r)-2-[(2r,3r,4r,5s,6r)-3-acetamido-2-[[[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoate
DTXSID701343741
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
UDP-N-acetylmuramate(3-)A nucleotide-sugar oxoanion arising from deprotonation of the carboxy and diphosphate OH groups of UDP-N-acetylmuramic acid; major species at pH 7.3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (19)

PathwayProteinsCompounds
Amino Sugar and Nucleotide Sugar Metabolism I1733
Peptidoglycan Biosynthesis I3036
Peptidoglycan Biosynthesis II3037
UDP-N-acetylmuramoyl-pentapeptide biosynthesis II (lysine-containing)926
UDP-N-acetylmuramoyl-pentapeptide biosynthesis I (meso-diaminopimelate containing)1738
UDP-N-acetylmuramoyl-pentapeptide biosynthesis III (meso-diaminopimelate containing)222
peptidoglycan biosynthesis V (u03B2-lactam resistance)138
peptidoglycan biosynthesis IV (Enterococcus faecium)336
O-antigen building blocks biosynthesis (E. coli)950
anhydromuropeptides recycling II819
anhydromuropeptides recycling I1348
peptidoglycan biosynthesis III (mycobacteria)1236
peptidoglycan biosynthesis I (meso-diaminopimelate containing)1142
peptidoglycan biosynthesis II (staphylococci)2044
UDP-N-acetyl-D-glucosamine biosynthesis I735
superpathway of UDP-N-acetylglucosamine-derived O-antigen building blocks biosynthesis2461
UDP-N-acetylmuramoyl-pentapeptide biosynthesis I (meso-DAP-containing)020
anhydromuropeptides recycling026
UDP-N-acetylmuramoyl-pentapeptide biosynthesis I (generic)016

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, UDP-N-acetylglucosamine 1-carboxyvinyltransferaseEscherichia coli K-12Ki0.90000.90000.90000.9000AID977610
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2009Biochemistry, Dec-15, Volume: 48, Issue:49
Evidence of kinetic control of ligand binding and staged product release in MurA (enolpyruvyl UDP-GlcNAc synthase)-catalyzed reactions .
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (323)

TimeframeStudies, This Drug (%)All Drugs %
pre-199036 (11.15)18.7374
1990's39 (12.07)18.2507
2000's88 (27.24)29.6817
2010's140 (43.34)24.3611
2020's20 (6.19)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.04 (24.57)
Research Supply Index5.79 (2.92)
Research Growth Index4.83 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews28 (8.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other299 (91.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]